Futura Medical Announces Collaboration to Commercialise MED3000 in key Latin American Markets

Futura Medical Announces Collaboration to Commercialise MED3000 in key Latin American Markets

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into a licensing agreement with m8 Pharmaceuticals, Inc (“m8”), a specialty biopharmaceutical company focused on commercialisation in Latin America, for the rights to exclusively develop and commercialise the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment MED3000, in Brazil and Mexico.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH